Clinical Trials
327
Active:4
Completed:96
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:10
Phase 2:13
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (228 trials with phase data)• Click on a phase to view related trials
Not Applicable
140 (61.4%)Phase 4
48 (21.1%)Phase 3
16 (7.0%)Phase 2
13 (5.7%)Phase 1
10 (4.4%)Early Phase 1
1 (0.4%)Temporal Interference Brain Stimulation Phase I Clinical Trial
Not Applicable
Recruiting
- Conditions
- Health AdultsTemporal Interference StimulationSafety and EffectivenessCrossover Study
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 80
- Registration Number
- NCT07179848
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Topical Versus Injection PRP for Olfactory Dysfunction
Not Applicable
Not yet recruiting
- Conditions
- Olfactory DysfunctionAnosmiaHyposmia
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 60
- Registration Number
- NCT07151703
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Digital Health Platform Blood Pressure Management Study
Not Applicable
Not yet recruiting
- Conditions
- Hypertension Prevention and Management
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 10000
- Registration Number
- NCT07147413
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 50
- Registration Number
- NCT07136545
- Locations
- 🇨🇳
Chang-Gung Memorial Hospital(Lin-Kou), Taoyuan District, Guishan District, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taipei city, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, taipei city, Taiwan
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Not Applicable
Not yet recruiting
- Conditions
- Glucagon-Like Peptide-1 Receptor AgonistsType 2 DiabetesCoronary Arterial Disease (CAD)
- Interventions
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 60
- Registration Number
- NCT07073053
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- 3
- 4
- 5
- 63
- Next
News
No news found